Oral administration of Escherichia coli in enteric coated microparticles induces serum antibodies against lipopolysaccharide antigens

Journal of Endotoxin Research

Volumn 3, Issue 6, 1996, Pages 481-489

  Flanagan, M P ^a   Battisti, G ^a   Michael, J G ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

BACTERIAL VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN;

EID: 0030462741     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300606     Document Type: Article

References (52)

1. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am J Trop Med Hyg 1994; 50: 42-54.
2. Taylor D.N., Trofa A.C., Sadoff J. et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993; 61: 3678-3687.
3. Mowat A.M. The regulation of immune responses to dietary protein antigens. Immunol Today 1987; 8: 93-98.
4. Shalaby W.S.W. Development of oral vaccines to stimulate mucosal and systemic immunity - barriers and novel strategies. Clin Immunol Immunopathol 1995; 74: 127-134.
5. Tomasi J.T. B. Oral tolerance. Transplantation 1980; 29: 353-355.
6. Michael J.G. The role of digestive enzymes in orally induced immune tolerance. Immunol Invest 1989; 18: 1049-1054.
7. Klipstein F.A., Engert R.F. Protective effect of active immunization with purified Escherichia coli heat-labile enterotoxin in rats. Infect Immun 1979; 23: 592-599.
8. Flanagan M.P., Wang C., Michael J.G. Characterization of the immune response following oral administration of modified antigen in an adjuvant-free system. J Immunol 1993; 150: 35.
9. Jain S.L., Barone K.S., Michael J.G. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen. Cell Immunol 1996; 167: 170-175.
10. Litwin A., Flanagan M.P., Entis G. et al. Oral immunotherapy with short ragweed employing a novel encapsulated preparation - a double-blinded study. Ann Allergy Asthma Immunol 1996; 77: 132-138.
11. Dougan D., Maskell D., O'Callaghan D., Chatfield S., Charles I., Hormaeche C. Oral vaccination. Antonie Van Leeuwenhoek 1988; 54: 447-451.
12. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
13. Tsai C-M., Frasch C.E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982; 119: 115-119.
14. Danneman P., Michael J.G. Adjuvant and immunogenic properties of bacterial lipopolysaccharide in IgE and IgG1 antibody formation in mice. Cell Immunol 1976; 22: 128-139.
15. Morrison D.C., Betz S.J. Lipopolysaccharide-lipid A associated protein (LAP) complexes. I. Chemical and biological properties of LAP. Fed Proc 1977; 36: 1234.
16. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990; 8: 321-326.
17. Kantele A., Arvilommi H., Kantele J.M., Rintala L., Makela P.H. Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. Microb Pathog 1991; 10: 117-126.
18. Robbins J.B., Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonella and shigella may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1992; 15: 346-361.
19. Chu C., Liu B., Watson D. et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae Type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun 1991; 59: 4450-4458.
20. Roberts J.A., Kaack M.B., Baskin G., Svenson S.B. Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate. Infect Immun 1993; 61: 5214-5218.
21. Watson D.C., Robbins J.B., Szu S.C. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 1992; 60: 4679-4686.
22. Cryz J.S.J., Cross A.S., Sadoff J.C., Wegmann A., Que J.U., Furer E. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 1991; 163: 1040-1045.
23. Ada G. Strategies for exploiting of the immune system in the design of vaccines. Molec Immunol 1991; 28: 225-230.
24. Gilligan C.A., Po A.L.W. Oral vaccines: design and delivery. Int J Pharm 1991; 75: 1-24.
25. Inman L.R., Cantey J.R. Specific adherence of Escherichia coli (strain RDEC-1) to membraneous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. J Clin Invest 1983; 71: 1-8.
26. Manganaro M., Ogra P.L., Ernst P.B. Oral immunization: turning fantasy into reality. Int Arch Allergy Immunol 1994; 103: 223-233.
27. McGhee J.R., Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis 1993; 2: 55-73.
28. McGhee J.R., Mestecky J., Dertzbaugh M., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10: 75-88.
29. Morris W., Steinhoff M.C., Russel P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12: 5-11.
30. O'Hagan D.T. Oral delivery of vaccines - formulation and clinical pharmacokinetic considerations. Clin Pharmacokinet 1992; 22: 1-10.
31. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994; 12: 387-400.
32. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas J.K., Gilley R.M., Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Controlled Release 1990; 11: 205-214.
33. Edelman R., Russell R.G., Lossonsky G. et al. Immunization of rabbits with an enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly(lactide-co-glycolide). Vaccine 1993; 11: 155-158.
34. McQueen C.E., Boedeker E.C., Reid R. et al. Pili in microspheres protect rabbits from diarrhoea induced by E. coli strain RDEC-1. Vaccine 1993; 11: 201-206.
35. Eldridge J.H., Staas J.K., Meulbroek J.A., McGhee J.R., Tice T.R., Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Molec Immunol 1991; 28: 287-294.
36. Moldoveanu Z., Novak M., Huang W.Q. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993; 167: 84-90.
37. O'Hagan D.T. Intestinal translocation of particulates - implications for drug and antigen delivery. Adv Drug Delivery Rev 1990; 5: 265-285.
38. Giannasca P.J., Neutra M.R. Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity. Infect Immun 1993; 2: 242-248.
39. Pelkonen S., Pluschke G. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection. Immunology 1989; 68: 260-264.
40. Mossman T.R., Coffman R.L. Th1 and Th2 cells: different pattern of lymphokine secretion leads to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
41. Jianchun X-A., Aicher W.K., Taguchi T., Kiyono H., McGhee J.R. Selective induction of Th2 cells in murine Peyer's patches by oral immunization. Int Immunol 1992; 4: 433-445.
42. Jackson R.J., Staats H.F., Xu-Amano J. et al. Oral vaccine models: multiple delivery systems employing tetanus toxoid. Ann NY Acad Sci 1994; 730: 217-234.
43. Kenney J.S., Hughes B.W., Masada M.P., Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Methods 1989; 121: 157-166.
44. Ahren C., Wenneras C., Holmgren J., Svennerholm A. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 1993; 11: 929-934.
45. Jertborn M., Svennerholm A., Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1992; 10: 130-132.
46. Jertborn M., Svennerholm A., Holmgren J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1993; 11: 1007-1012.
47. Rollwagen F., Pacheco N., Clements J., Pavlovskis O., Rollins D., Walker R. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine 1993; 11: 1316-1320.
48. Yeung S., Pang G., Cripps A.W, Clancy R.L., Wlodarczyk J.H. Efficacy of oral immunization against non-typable Haemophilus influenza in man. Int J Immunopharm 1987; 9: 283-288.
49. Junginger H.E. Bioadhesive polymer systems for peptide delivery. Acta PharmTechnol 1990; 36: 110-126.
50. Orr N., Robin G., Cohen D., Arnon R., Lowell G.H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 1993; 61: 2390-2395.
51. Kido N., Ohta M., Ito H., Nagase F., Nakashima I., Kato N. Potent adjuvant action of lipopolysaccharides possessing O-specific polysaccharide moieties consisting of mannans in antibody response against protein antigen. Cell Immunol 1985; 91: 52-59.
52. Applemelk B.J., vanVught A.M.V., Maaskant J.J., Schouten W.F., Thijs L.G., Maclaren D.M. Use of mucine and hemoglobin in experimental murine Gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccha